Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Novalgen Ltd.Startup |
Active Organization Novalgen Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | GB | Novalgen Ltd.Startup | 22 Apr 2024 |